BU-NOT-SET

CONTACT US
The Recipharm Journey
  • Corporate
Eyes
Insight
Solubility enhancement
  • Drug substance
Man holding liquid container
Fact sheet
Unlocking the key changes to Annex 1
  • Manufacturing
Eyes
Insight
Trends impacting drug dosage forms
  • Drug product
Product line
Insight
Relocation of the production of pharmaceuticals: a strategic endeavour for the European Union
  • Industry trends
Eyes
Insight
Outsourcing solid dose manufacturing trends
  • Manufacturing
Eyes
Insight
Strategic outsourcing of analytical testing solutions to speed up time-to-market
  • Analytical chemistry
Eyes
Insight
Recipharm Cannabinoids
  • Drug product
Eyes
Insight
Explore Recipharm's Full Service Offering
  • Corporate
Recipharm_packaging
Brochure
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field